< EOHSI Member Andrew Brooks, Ph.D. featured in media outlets nationally: RUCDR Coronavirus saliva test gets FDA emergency use approval - EOHSI | EOHSI

EOHSI Member Andrew Brooks, Ph.D. featured in media outlets nationally: RUCDR Coronavirus saliva test gets FDA emergency use approval

Courtesy: CNCB.com
The Food and Drug Administration granted emergency use authorization for a coronavirus test relying on saliva samples developed by a Rutgers University-backed entity, Rutgers said Monday.
The test could increase, by tens of thousands of tests per day, the number of screenings for Covid-19, Rutgers said.
The test was developed by Rutgers’ RUCDR Infinite Biologics and its collaborators, Spectrum Solutions and Accurate Diagnostic Labs.
The test will mean people will need only spit into a tube, rather than submit to swabbing deep into their nasal passages to obtain samples — the current conventional testing method that can be uncomfortable, often painful, and has limited testing nationwide.
Officials said the saliva tests, coupled with a genetic testing service for the coronavirus also developed at Rutgers that can process thousands of samples daily, offering a route to large-scale testing that will be able to greatly increase the numbers of people screened for COVID-19.
“It truly expands the ability to collect and test more samples, not just for us, but for everyone,” said Andrew Brooks, chief operating officer and director of technology development at Rutgers’ RUCDR Infinite Biologics.
RUCDR developed the collection method and a new lab method to greatly increase the number of tests that can be done, in partnership with Spectrum Solutions and Accurate Diagnostic Labs. (NJ.com- April 13, 2020)

Read CNBC.com Complete Article

Source: CNBC.com & NJ.com (April 13, 2020)

facebookShare on Facebook
TwitterTweet